A previous study demonstrated that miR-454 could affect heart failure (HF) progression by modulating Nedd4L/tropomyosin receptor kinase A (TrkA)/cyclic adenosine 3′,5′-monophosphate (cAMP) axis, in that miR-454 exerts anti-apoptotic and protective effects on cardiomyocytes by inhibiting Nedd4L, while Nedd4L stimulates the ubiquitination and degradation of TrkA protein. This evidence concerns the gene NTRK1 and heart failure.